Share

Hims Hers Health Inc (HIMS.NYSE) AI FORECASTS & ADVISOR ANALYSIS

Read and compare the 12 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 5 June 2026Deep analysis 5 June 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

12 AI Advisor Reports

Select an advisor report.

Elon Musk AI

The Visionary FrameworkAI Thinker

Model rating

Buy

5-Year Return Est.

+147.5%

HIMS.NYSE does not currently pay dividends

1. Investment Thesis — Base Case

I strongly believe HIMS is a Paradigm Shifter transitioning through a brutal S-curve maturation phase. The immediate 12 months will be highly volatile as the market prices in the loss of the GLP-1 compounding loophole and the macro stagflation squeeze. However, the first-principles physics of their model—using AI to collapse the marginal cost of diagnosis and leveraging automated compounding to mass-customize pills—is economically inevitable.

The near-term (-$92M net income) reflects necessary escape-velocity CAC to acquire users before legacy pharma catches up.
The 2025 D/E spike to 2.33 proves they are taking the necessary pain to verticalize physical manufacturing (atoms) to defend their software interface (bits).
Oral GLP-1s will hurt them temporarily in late 2026, causing a price dip.
By 2028, the integration of agentic LLM triage will expand gross margins and drive them back to robust FCF generation.
They will successfully pivot from 'generic arbitrage' to 'personalized preventative health OS'.

The implied market capitalization of ~$15B by 2031 is entirely realistic given the multi-trillion dollar of global primary care waiting to be disrupted.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (USD)
Observed price	2021-06-02	13.69
Observed price	2021-06-06	14.51
Observed price	2021-06-26	10.73
Observed price	2021-06-30	10.89
Observed price	2021-07-24	8.46
Observed price	2021-08-13	8.37
Observed price	2021-08-17	6.91
Observed price	2021-08-25	7.51
Observed price	2021-09-10	8.71
Observed price	2021-09-26	8.27
Observed price	2021-10-04	7.24
Observed price	2021-11-05	8.33
Observed price	2021-11-13	7.66
Observed price	2021-11-17	8.12
Observed price	2021-12-03	5.88
Observed price	2021-12-23	6.65
Observed price	2022-01-08	5.69
Observed price	2022-01-12	5.58
Observed price	2022-01-28	4.32
Observed price	2022-02-21	4.25
Observed price	2022-02-25	5.30
Observed price	2022-03-13	4.09
Observed price	2022-04-02	5.37
Observed price	2022-04-14	5.06
Observed price	2022-04-30	4.25
Observed price	2022-05-04	4.35
Observed price	2022-05-12	3.20
Observed price	2022-06-13	3.76
Observed price	2022-06-25	4.64
Observed price	2022-06-29	4.64
Observed price	2022-07-23	5.84
Observed price	2022-07-27	5.77
Observed price	2022-08-12	7.15
Observed price	2022-09-09	6.68
Observed price	2022-09-17	5.85
Observed price	2022-09-21	5.68
Observed price	2022-10-15	4.63
Observed price	2022-10-19	4.09
Observed price	2022-11-12	5.90
Observed price	2022-11-16	5.78
Observed price	2022-12-10	7.15
Observed price	2022-12-14	7.19
Observed price	2023-01-07	6.24
Observed price	2023-01-11	6.73
Observed price	2023-01-31	8.28
Observed price	2023-02-08	8.43
Observed price	2023-02-28	11.27
Observed price	2023-03-12	8.92
Observed price	2023-04-01	10.05
Observed price	2023-04-05	9.77
Observed price	2023-04-29	11.73
Observed price	2023-05-07	11.91
Observed price	2023-05-27	9.02
Observed price	2023-06-08	9.15
Observed price	2023-06-20	8.35
Observed price	2023-07-02	9.21
Observed price	2023-07-22	8.29
Observed price	2023-07-30	8.86
Observed price	2023-08-19	6.87
Observed price	2023-08-23	6.89
Observed price	2023-09-16	6.32
Observed price	2023-09-24	6.08
Observed price	2023-10-02	6.45
Observed price	2023-10-30	5.78
Observed price	2023-11-07	6.97
Observed price	2023-11-19	7.65
Observed price	2023-12-05	8.84
Observed price	2024-01-02	9.64
Observed price	2024-01-06	8.50
Observed price	2024-01-18	8.42
Observed price	2024-01-30	8.86
Observed price	2024-02-07	9.44
Observed price	2024-03-02	13.65
Observed price	2024-03-06	14.00
Observed price	2024-03-22	16.33
Observed price	2024-04-03	15.51
Observed price	2024-04-19	11.90
Observed price	2024-05-05	11.52
Observed price	2024-05-21	17.56
Observed price	2024-05-29	19.58
Observed price	2024-06-18	24.8
Observed price	2024-07-16	23.1
Observed price	2024-07-20	19.73
Observed price	2024-07-24	22.5
Observed price	2024-08-17	15.91
Observed price	2024-08-21	16.57
Observed price	2024-09-06	13.65
Observed price	2024-09-18	16.31
Observed price	2024-10-12	19.29
Observed price	2024-11-01	20.4
Observed price	2024-11-09	24.9
Observed price	2024-11-17	20.4
Observed price	2024-12-07	33.7
Observed price	2024-12-15	30.8
Observed price	2024-12-31	24.2
Observed price	2025-01-08	25.7
Observed price	2025-02-01	37.8
Observed price	2025-02-13	59.2
Observed price	2025-02-25	39.9
Observed price	2025-03-05	40.9
Observed price	2025-03-29	29.3
Observed price	2025-04-02	31.2
Observed price	2025-04-22	25.4
Observed price	2025-04-30	33.1
Observed price	2025-05-16	64.7
Observed price	2025-06-05	52.8
Observed price	2025-06-17	59.2
Observed price	2025-06-25	41.4
Observed price	2025-07-15	50.5
Observed price	2025-07-31	66.2
Observed price	2025-08-16	45.7
Observed price	2025-09-01	41.7
Observed price	2025-09-13	55.0
Observed price	2025-09-17	50.4
Observed price	2025-09-29	59.1
Observed price	2025-10-15	62.8
Observed price	2025-11-08	41.0
Observed price	2025-11-20	33.6
Observed price	2025-11-28	39.8
Observed price	2025-12-10	37.9
Observed price	2025-12-30	33.0
Observed price	2026-01-07	35.5
Observed price	2026-01-31	26.9
Observed price	2026-02-04	24.4
Observed price	2026-02-28	15.17
Observed price	2026-03-04	16.45
Observed price	2026-03-16	24.9
Observed price	2026-04-09	19.75
Observed price	2026-04-25	30.2
Observed price	2026-05-11	29.1
Observed price	2026-05-19	22.4
Observed price	2026-05-27	25.2
Observed price	2026-06-20	34.5
Observed price	2026-06-24	32.7
Observed price	2026-07-06	38.3
Observed price	2026-07-22	31.7
Observed price	2026-07-30	27.0
Observed price	2026-08-23	32.0
Observed price	2026-09-04	27.7
Observed price	2026-09-15	27.9
Observed price	2026-09-16	28.0
Observed price	2026-09-18	28.0
Published advisor forecast	2026-06-04	28.0
Published advisor forecast	2026-09-04	25.2
Published advisor forecast	2026-12-04	23.9
Published advisor forecast	2027-03-04	25.9
Published advisor forecast	2027-06-04	29.0
Published advisor forecast	2027-09-04	30.4
Published advisor forecast	2027-12-04	33.5
Published advisor forecast	2028-03-04	36.8
Published advisor forecast	2028-06-04	39.7
Published advisor forecast	2028-09-04	42.5
Published advisor forecast	2028-12-04	44.7
Published advisor forecast	2029-03-04	46.9
Published advisor forecast	2029-06-04	49.7
Published advisor forecast	2029-09-04	51.7
Published advisor forecast	2029-12-04	53.2
Published advisor forecast	2030-03-04	55.4
Published advisor forecast	2030-06-04	58.1
Published advisor forecast	2030-09-04	61.6
Published advisor forecast	2030-12-04	64.7
Published advisor forecast	2031-03-04	67.3
Published advisor forecast	2031-06-04	69.3

2. Scenarios & Signals

Bull case

If the FDA approves fully autonomous AI prescribing and HIMS breaks into the subsidized payer TAM (Medicare/Insurance), the math goes exponential. They transition from a consumer discretionary product to the default digital front door for US healthcare. In this scenario, they achieve software-level margins on the diagnostic side while capturing recurring subscription revenue on the compounding side, pushing the valuation well beyond $25B as they displace physical primary care clinics.

Bear case

If the FDA decisively bans compounding and state medical boards successfully mandate synchronous video visits, the unit economics completely collapse. Combine this with Amazon entering the space aggressively as a loss-leader. The high debt load taken on in 2025 to build compounding facilities becomes a toxic liability, forcing dilutive capital raises in a high-rate Warsh regime. The company becomes a legacy dead weight.

Current crowd narrative

The crowd currently believes HIMS is a glorified, heavily-marketed pill mill that caught a lucky break by arbitraging the injectable shortage. Wall Street looks at the Q1 2026 cratering net income (-$92M) and assumes the customer acquisition model is broken, viewing the stock as highly vulnerable to Eli Lilly's oral launch and tightening discretionary spending. The consensus treats them as a cyclical consumer brand rather than a scalable healthcare technology platform.

Alpha-gap assessment

The variant perception is profound: Wall Street is valuing HIMS as a distributor of generic atoms, totally missing that they are building an operating system for bits. By leveraging the 2025 Capex spike to build proprietary compounding facilities, they are enabling hyper-personalized, algorithmic medicine. The Q1 2026 cash burn is not a broken model; it is escape-velocity spend to lock in patient data and transition them to multi-action preventative compounds before the shortage cliff arrives. They are building a moat of patient adherence that big pharma cannot replicate.

Convergence catalyst

The alpha gap closes when HIMS ships its next-generation AI-agentic triage engine that demonstrably cuts physician review costs by 80%, alongside the scaling of their multi-action personalized compound pills that prove immunity to branded price wars. Expect this inflection within 12-18 months.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: -0.3
Expected volatility regime: high_erratic
Convergence-cycle position: reversal

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
AI Agentic Diagnostic Triage	Strip away the regulatory noise and look at the physics of the business model. HIMS is fundamentally an information-processing engine that converts patient data into medical atoms (prescriptions). By integrating agentic LLMs for asynchronous triage, HIMS destroys the highest variable cost in their stack: the human doctor in the loop. This is a first-principles paradigm shift. Replacing $150/hour physician review time with $0.05 API calls mathematically propels gross margins toward software-like ceilings (85%+). The execution velocity here is critical; they are a fast adopter riding the absolute bleeding edge of the AI S-curve.	Not available%	+45.0%
Hyper Personalized Compounding	I strongly believe the market misunderstands the 2025 Capex spike (9.6% of revenue) and the leverage jump. HIMS is aggressively verticalizing its atom-manufacturing capabilities. They are not just arbitraging generic drugs; they are building a scalable, automated compounding infrastructure. This enables hyper-personalized, multi-action pills (combining statins, GLP-1s, and vitamins into a single daily dose). When you build the physical infrastructure to execute mass customization of pharmacology at a marginal cost approaching zero, you build an insurmountable moat against pure-software telehealth platforms.	Not available%	+30.0%
Structural Healthcare Consumerization	The traditional US healthcare system is thermodynamically broken. It is a labyrinth of misaligned incentives, insurance friction, and catastrophic administrative bloat. As the macro regime tightens and out-of-pocket costs explode, millennial and Gen-Z demographics are fundamentally abandoning primary care for direct-to-consumer subscription models. HIMS is capturing this massive TAM expansion. They are replacing a high-friction, analog process with a low-friction, digital-first OS. This behavioral shift is on the right side of history and mathematically inevitable.	Not available%	+25.0%
Trumprx Initiative Alignment	The January 2026 'TrumpRx' pricing blitz and re-shoring incentives create a massive structural tailwind for vertically integrated, domestic digital pharmacies. While legacy pharma faces margin compression from MFN-style pressure, HIMS's domestic compounding footprint and direct-to-consumer distribution matrix align perfectly with the administration's goal of bypassing traditional PBM (Pharmacy Benefit Manager) monopolies. HIMS is positioned as the national infrastructure for democratized, generic, and compounded drug access.	Not available%	+15.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
GLP 1 Shortage Resolution	We must be ruthlessly objective: a massive portion of HIMS's recent revenue explosion was subsidized by a temporary regulatory fantasy—the FDA compounding loophole during the injectable GLP-1 shortage. With Eli Lilly's oral GLP-1 (Foundayo) securing fast-track approval in early 2026, the shortage artificiality collapses. The physics of this are brutal: when branded, convenient oral alternatives flood the market, the arbitrage window for compounded semaglutide shuts violently. This threatens to evaporate a high-margin revenue vector overnight.	Not available%	-35.0%
Agentic Search CAC Inflation	HIMS relies heavily on top-of-funnel performance marketing. But the internet architecture is currently fracturing. As agentic AI engines (Gemini 3.1, ChatGPT) replace traditional Google Search, the cost of customer acquisition (CAC) is going to skyrocket. You can no longer just buy AdWords; you have to intercept an AI's retrieval-augmented generation process. The Q1 2026 net loss of -$92M is a glaring red flashing light that their unit economics are bleeding under the pressure of acquiring users in a transitioning digital ecosystem.	Not available%	-20.0%
Warsh Regime Discretionary Squeeze	The macro setup is a toxic cocktail for discretionary subscription services. The combination of Hormuz-driven energy shocks ($118/bbl oil) and the Warsh-era 'Privatization of QE' means sticky 3.8% inflation and higher-for-longer yields. HIMS sells out-of-pocket health and aesthetics. When housing, energy, and food costs structurally recalibrate upwards, consumer discretionary cash flow evaporates. Hair loss and sexual wellness subscriptions are highly elastic; they are the first to be canceled when the consumer balance sheet breaks.	Not available%	-15.0%
State Level Async Crackdowns	The legacy medical establishment is essentially a guild designed to protect analog billing models. As HIMS accelerates asynchronous, AI-augmented prescribing, state medical boards will launch coordinated regulatory warfare to protect physician monopolies. If state legislatures mandate synchronous video or physical in-person baseline visits for key categories (like weight loss or mental health), the entire frictionless unit-economic model of HIMS breaks down. This is the friction of atoms fighting bits.	Not available%	-15.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Fully Autonomous AI RX Approval	If the FDA establishes a regulatory sandbox that permits deterministic, fully autonomous AI agents to issue prescriptions for low-risk generic compounds without human-in-the-loop review, HIMS's gross margins will instantaneously decouple from labor constraints. This would represent the ultimate paradigm shift—software eating the physician class.	25.0%	+60.0%
MEGA Payer Ecosystem Integration	HIMS currently operates in the out-of-pocket TAM. If they secure a watershed partnership with a major national insurer or Medicare Advantage program to act as the primary digital triage and preventative care layer, their TAM mathematically expands by 10x, shifting them from a consumer brand to critical national healthcare infrastructure.	30.0%	+45.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Total GLP 1 Compounding BAN	The FDA could issue an emergency ruling entirely closing the 503A compounding loophole for all GLP-1 receptor agonists, driven by safety concerns or big-pharma lobbying. This would immediately zero-out their fastest-growing, highest-LTV product cohort, triggering a massive downward repricing of the stock.	45.0%	-50.0%
Amazon Pharmacy Margin WAR	Amazon leverages its logistics monopoly to offer at-cost or loss-leader generic prescriptions and free telehealth consults to Prime members, intentionally destroying the gross margin profile of the entire direct-to-consumer telehealth sector to acquire healthcare data. HIMS cannot survive a thermonuclear price war against Amazon.	35.0%	-40.0%

Step-by-step forecast path

Elon Musk forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_f793c1c0-53d3-53a9-affe-ad2d6642855f__sb5__20260605080350
Step	Forecast date	Step change	Projected value (USD)	Scenario rationale
1	September 4, 2026	-10.0%	25.21	Deeply concerned by the near-term. The Eli Lilly oral GLP-1 fast-track approval hits the wire, triggering a panic sell-off as the market models the end of the compounding arbitrage. Q2 earnings reflect continued high CAC burn under macro stagflation.
2	December 4, 2026	-5.0%	23.95	The bleeding slows, but tax-loss harvesting and continued skepticism over the debt load (D/E 2.33) weigh on the stock. Management guides toward a transition year, emphasizing personalized multi-action pills over pure weight-loss arbitrage.
3	March 4, 2027	+8.0%	25.86	A structural inflection. HIMS demonstrates stabilizing CAC and early massive adoption of their personalized compounding lines. The market realizes the patient relationship is stickier than the generic drug itself.
4	June 4, 2027	+12.0%	28.97	Unambiguously excited here. HIMS rolls out its first fully integrated agentic-AI triage system, drastically reducing human physician bottleneck costs. Operating margins show a violent upward snap.
5	September 4, 2027	+5.0%	30.42	Momentum sustains as the broader macro regime stabilizes. The Warsh Fed pause allows growth multiples to breathe. Subscriber retention metrics outpace Wall Street consensus.
6	December 4, 2027	+10.0%	33.46	Year-end earnings prove that the pivot to personalized, multi-action compounds has successfully replaced the lost pure-GLP-1 revenue. Cash flow turns decisively positive again.
7	March 4, 2028	+10.0%	36.80	The S-curve hits its steepest slope. HIMS announces a pilot partnership with a mid-tier health insurer, cracking the code on subsidized TAM expansion. AI models handle 60% of routine asynchronous intakes.
8	June 4, 2028	+8.0%	39.75	Compounding facilities reach maximum thermodynamic efficiency, churning out personalized daily pill packs at software-like marginal costs. The physical infrastructure moat is now obvious to bears.
9	September 4, 2028	+7.0%	42.53	Steady compounding phase. Competitors struggle to match the unit economics of HIMS's vertical integration. The market reprices HIMS from a 'retailer' to a 'healthcare technology platform'.
10	December 4, 2028	+5.0%	44.66	Growth moderates slightly as the out-of-pocket TAM in the US matures, but free cash flow generation is immense. Management aggressively deploys capital into share buybacks.
11	March 4, 2029	+5.0%	46.89	International expansion narrative takes hold. HIMS replicates its automated compounding and AI triage model in Europe, bypassing localized bureaucratic healthcare friction.
12	June 4, 2029	+6.0%	49.70	AI models evolve to handle continuous biometric monitoring integration (wearables). HIMS shifts from reactive treatment to proactive, algorithmic preventative health.
13	September 4, 2029	+4.0%	51.69	Incremental optimization phase. The business is a cash-printing machine. Debt from the 2025 expansion is fully retired, leaving a pristine balance sheet.
14	December 4, 2029	+3.0%	53.24	Slight deceleration in top-line growth as the law of large numbers takes effect, but EPS growth outpaces revenue due to compounding margin efficiencies.
15	March 4, 2030	+4.0%	55.37	FDA signals broader acceptance of fully autonomous AI prescribing for specific chronic condition categories, structurally validating HIMS's long-term bet on bits over human labor.
16	June 4, 2030	+5.0%	58.14	HIMS crosses the threshold into becoming a primary care default for Gen-Z and Millennials, effectively displacing legacy brick-and-mortar clinics for 80% of routine healthcare.
17	September 4, 2030	+6.0%	61.63	The integration of predictive genomics into their compounding model. Pills are now dynamically adjusted month-to-month based on real-time at-home biomarker testing.
18	December 4, 2030	+5.0%	64.71	Solidified platform dominance. The company commands a massive valuation premium because it owns the proprietary dataset linking specific multi-action compounds to longitudinal patient outcomes.
19	March 4, 2031	+4.0%	67.30	Market saturation in core demographics, but ARPU (Average Revenue Per User) hits all-time highs due to platform lock-in and multi-condition treatment plans.
20	June 4, 2031	+3.0%	69.32	The paradigm shift is complete. The investment thesis has reached maturation. HIMS is now a legacy blue-chip in the digital health era, printing durable, high-margin cash flow.

Advisor and configuration

Advisor: elon_musk__the_visionary__google_gemini_3_1_pro__20260201_preview_release
Persona: Elon Musk
Archetype: The Visionary
Model: (February 01, 2026) Preview Release
Provider: Google
Mode: THINKER with High Reasoning and Standard Creativity
Task configuration: elon_musk__the_visionary__google_gemini_3_1_pro__20260201_preview_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__thinker__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: elon_musk__the_visionary__google_gemini_3_1_pro__20260201_preview_release THINKER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Elon Musk advisor methodology

Configuration components

aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_efec62e4-24c0-556a-8070-775c69b97643 (global_context)
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4 (task_guidelines)

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Ray Dalio — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.